Message #4 From:
NewsBot Date: July 28, 2006 06:40:00 AM
HBSC News Market News First (mn1.com) to Interview Harry Masuda, CEO of Human BioSystems on HBSC's Breaking News
PALO ALTO, Calif.--(BUSINESS WIRE)--July 28, 2006--Human BioSystems (OTCBB:HBSC), announced today that Harry Masuda, CEO, will be interviewed by Market News First Radio (www.mn1.com), Friday (28 July 2006) at 10:00 am EDT.
In this exclusive interview, Mr. Masuda will brief the listening audience on the Letter of Intent that Human BioSystems just signed to acquire two ethanol production facility projects from EXL III Group Corporation ("EXL III"), an equity partner in ethanol plant ventures.
At the close of the market on Thursday, July 27, 2006, Mr. Masuda, CEO of Human BioSystems, stated in a news release, "We made the decision to enter the bio energy field because it gives HBS the potential to achieve substantial revenue and profit growth within a predictable timetable, and because the opportunity and expertise to pursue the renewable energy market exists with this acquisition. This acquisition should give HBS additional financing options not previously available," continued Mr. Masuda.
HumanBioSystems, a developer of preservation platforms for organs and other biomaterials, specializing in the development of proprietary above zero ("HBS-AZ") and below zero ("HBS-BZ") organ and tissue preservation systems and methods for preserving blood platelets, has made tremendous advancements in their research and testing of their proprietary preservation methods over the past year and is now beginning the process to prepare their application to the FDA to obtain a license to begin performing human testing.
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for human studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, issues with the patentability and/or protection of the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
